The LFOR-3 delivers a payload of magnetically responsive ferrofluid nanoparticles via a pressurized aerosol bolt that disperses on skin contact and penetrates subcutaneously through follicular and sweat gland channels. Once embedded in the subcutaneous tissue, an external magnetic pulse from the rifle's secondary emitter aligns and compacts the particles within lymphatic capillaries, causing immediate mechanical occlusion. The resulting blockage triggers rapid localized lymphedema — extreme fluid accumulation in the affected limb or region.

The swelling is not merely cosmetic. Within minutes, the pressure in occluded tissue exceeds compartment syndrome thresholds, causing excruciating pain, loss of motor function, and if untreated, tissue necrosis. The weapon can be tuned to affect a single limb or, with a wider dispersal bolt, to seed multiple lymphatic regions simultaneously. Unlike many exotic weapons in its class, the LFOR-3 is deliberately designed for survivability — the manufacturer positions it as a 'non-lethal incapacitation system' — though death from secondary infection or untreated compartment syndrome is common in populations without access to quality medical care.

Helix Biosystems developed the ferrostatic occlusion mechanism from research into targeted lymphatic drug delivery. The weaponized application was funded through a subsidiary with deliberately obscured corporate parentage. The rifle is now quietly distributed to private security firms as a 'humane deterrent,' with Helix maintaining that adverse outcomes are the result of inadequate post-exposure medical response rather than the weapon itself.